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ANALYSIS OF DRUG INTERACTIONS WITH HIGH DENSITY
LIPOPROTEIN BY HIGH-PERFORMANCE AFFINITY
CHROMATOGRAPHY
Sike Chen, Matthew R. Sobansky, and David S. Hage*
Chemistry Department University of Nebraska Lincoln, NE 68588-0304 (USA)
Abstract
Columns containing immobilized lipoproteins were prepared for the analysis of drug interactions
with these particles by high-performance affinity chromatography. This approach was evaluated by
using it to examine the binding of high density lipoprotein (HDL) to the drugs propranolol or
verapamil. HDL was immobilized by the Schiff base method onto silica and gave HPLC columns
with reproducible binding to propranolol over four to five days of continuous operation at pH 7.4.
Frontal analysis experiments indicated that two types of interactions were occurring between R/S-
propranolol and HDL at 37°C: saturable binding with an association equilibrium constant (Ka) of
1.1–1.9 × 105 M−1, and non-saturable binding with an overall affinity constant (n Ka) of 3.7–4.1 ×
104 M−1. Similar results were found at 4 and 27°C. Verapamil also gave similar behavior, with a
Ka of 6.0 × 104 M−1 at 37°C for the saturable sites and a n Ka value for the non-saturable sites of 2.5
× 104 M−1. These measured affinities gave good agreement with solution-phase values. The results
indicated HPAC can be used to study drug interactions with HDL, providing information that should
be valuable in obtaining a better description of how drugs are transported within the body.
Keywords
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INTRODUCTION
The binding of drugs with proteins, cell receptors, enzymes, immunoglobins and other
biological agents is important in determining the activity, pharmacokinetics and toxicity of
these drugs in the human body [1–3]. Many drugs can also undergo reversible interactions with
serum proteins and lipoproteins in blood. These interactions typically have association
equilibrium constants or overall affinities in the range of 103 to 106 M−1 and can play an
important role in affecting the distribution, delivery, metabolism, and excretion of drugs [1–
6]. As a result, the pharmaceutical industry often performs binding studies with these agents
when designing a new drug and when determining which mode of drug delivery might treat a
disease most efficiently [3,4,7].
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As shown in Figure 1(a), a lipoprotein is a soluble macromolecular complex of proteins and
lipids that transports hydrophobic compounds such as cholesterol and triglycerides [7–9]. In
humans, lipoproteins are classified according to their density, giving categories that include
low density lipoprotein (LDL) and high density lipoprotein (HDL) [7,9,11–15]. In addition to
binding cholesterol and triglycerides, these lipoproteins are also known to bind several basic
or neutral drugs in blood [10].
Two drugs known to bind with HDL are propranolol and verapamil (see structures in Figure
1(b–c)). Equilibrium dialysis has previously been used to examine the binding of racemic
propranolol with HDL [16]. High-performance frontal analysis/capillary electrophoresis has
also been utilized to study interactions of propranolol, verapamil and other drugs to HDL or
other lipoproteins [17–19]. Table 1 summarizes the binding constants that have been measured
for propranolol and verapamil with HDL in these reports [16–18]. These earlier studies have
used a model based on a single, non-saturable interaction between HDL and propranolol or
verapamil, with estimated overall affinities (nKa) in the range of 104 M−1 [16–18].
In this study, high-performance affinity chromatography (HPAC) will be evaluated and
employed as a tool to provide a more detailed analysis of the interactions between HDL and
propranolol or verapamil. HPAC has been successfully utilized in the past to examine the
binding of drugs with serum proteins such as human serum albumin (HSA) and α1-acid
glycoprotein (AGP) [3–6,20–26]. However, no known previous reports have used HPAC to
examine drug interactions with lipoproteins. The advantages of using HPAC for such work
include the speed, ease of automation, and precision of this method; this technique has also
been shown in many drug binding studies with HSA, and more recently with AGP, to give
good correlation versus solution-phase reference methods [3,5,6,20,21,24].
In this report, columns containing immobilized HDL will first be prepared and their stability
will be examined through zonal elution studies. Binding of the immobilized HDL to
propranolol and verapamil will then be investigated by using frontal analysis. The results will
be compared to data obtained in previous work with soluble HDL. These experiments should
make it possible to determine the feasibility of using immobilized lipoproteins such as HDL
in drug binding studies based on HPAC. The results should also provide further information
regarding the nature of the interactions between propranolol and verapamil with HDL and give
a more complete picture of how these drugs are transported in blood. This information should
be valuable in future work as this approach is applied to other drugs and lipoproteins.
EXPERIMENTAL
Reagents
The human HDL (catalog number L1567, lot no. B73112), separate enantiomers of R- and S-
propranolol, and racemic R/S-verapamil were purchased from Sigma (St. Louis, MO, USA).
Nucleosil Si-300 silica (7 μm particle diameter, 300 Å pore size) was obtained from Macherey
Nagel (Düren, Germany). Reagents for the bicinchoninic acid (BCA) protein assay were from
Pierce (Rockford, IL, USA). An assay kit for measuring total cholesterol was purchased from
Wako (Richmond, VA, USA). All other chemicals were of the highest grades available. All
solutions were prepared using water from a Nanopure purification system (Barnstead,
Dubuque, IA, USA) that was filtered using Osmonics 0.22 μm nylon filters from Fisher
Scientific (Pittsburgh, PA, USA).
Apparatus
This chromatographic system consisted of two PU-980 pumps (Jasco, Tokyo, Japan), one
LabPro injection valve (Rohnert Park, FL, USA), and a UV/Vis SpectroMonitor 3200 variable
wavelength absorbance detector from LDC Thermoseparations (Riviera Beach, FL, USA).
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Chromatographic data were collected and processed using programs based on Labview 5.1 or
7.0 (National Instruments, Austin, TX, USA). Support materials were placed into columns
using a slurry packer from Alltech (Deerfield, IL, USA). A PolyScience circulating water bath
(VWR, Buffalo Grove, IL, USA) was used to control the temperature of the columns and mobile
phases.
Preparation of HDL silica
The reactions used to prepare the HDL silica are shown in Figure 2. First, diol-bonded silica
was prepared from Nucleosil Si-300 silica by using a previously published procedure (Step 1
in Figure 2) [24,25]. A modified form of the Schiff base method was used to attach HDL to
this support [23]. In this method, 0.2 g of diol-bonded silica was placed into 4 ml of a 90:10
(v/v) mixture of acetic acid and water, to which was then added 0.2 g periodic acid (Step 2).
This mixture was sonicated under vacuum for 15 min and placed on a wrist action shaker for
over 2 h in the dark at room temperature. The resulting aldehyde-activated silica was washed
six times with water and four times with pH 6.0, 0.10 M potassium phosphate buffer.
The aldehyde silica was suspended in 1 ml of pH 6.0, 0.10 M potassium phosphate buffer and
sonicated for 5 min under vacuum. A 20 mg portion of HDL and 4.3 mg of sodium
cyanoborohydride (NaCNBH4) were added to this slurry (Step 3). This mixture was shaken in
the dark at 4 °C for 3 days. The resulting immobilized HDL support was washed four times
with pH 7.0, 0.10 M potassium phosphate buffer. A 3.4 mg portion of sodium borohydride
(NaBH4) was dissolved into 2 ml of pH 7.0, 0.10 M potassium phosphate buffer and added to
the HDL support to reduce any remaining aldehyde groups on the silica and to eliminate non-
specific biding that might later occur with such groups. This mixture was shaken for 90 min
at room temperature. The final HDL support was washed six times using pH 7.0, 0.10 M
potassium phosphate buffer. The HDL support was stored in the same pH 7.0 buffer at 4 °C
until use. A separate portion of diol silica, as made in Step 1 in Figure 2, was used as the control
support in this study.
The protein content of the HDL support was evaluated by using a BCA protein assay [27,28].
An HDL stock solution was prepared in pH 7.4, 0.067 M potassium phosphate buffer and serial
dilutions of this stock solution were made to prepare standards for generating a calibration
curve. Diol silica was utilized as the blank. After reacting with the BCA reagents, all samples
and standard solutions were filtered through a 0.2 μm nylon filter prior to obtaining absorbance
readings for their supernatants at 562 nm.
An assay for the total cholesterol content of the HDL silica was performed with a commercial
kit based on an enzymatic colorimetric method [28,30]. In this assay, diol silica was again used
as the blank. A calibration curve was prepared by using the standard solution provided with
the assay kit and diluting this solution with pH 7.4, 0.067 M potassium phosphate buffer. The
HDL silica and diol silica control support were suspended in this buffer and an aliquot of a
working reagent solution, prepared from the color reagent and buffer solution provided with
the assay kit, was added to all samples and standards according to the manufacturer's
instructions. After the samples and standards were allowed to react with the reagent, each
sample or standard was passed through a 0.22 μm nylon filter before measuring the absorbance
of its supernatant at 600 nm.
Chromatographic studies
The HDL silica and diol silica control support were downward slurry packed at 24 MPa (3500
psi) into 1 cm × 2.1 mm i.d. or 5 cm × 2.1 mm i.d. stainless steel columns using pH 7.4, 0.067
M potassium phosphate buffer as the packing solution. The HDL and control columns were
stored in pH 7.4, 0.067 M potassium phosphate buffer at 4°C when not in use. Prior to the
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chromatographic studies, these columns were placed into water jackets from Alltech and
connected to a circulating water bath for temperature control (± 0.1°C). All mobile phases were
filtered through 0.22 μm nylon filters and degassed under vacuum over 15 min before use on
the chromatographic system. The wavelength used to monitor the elution of R- or S-propranolol
was 225 nm, and a wavelength of 229 nm was used for verapamil. The elution of sodium nitrate,
which was employed as a non-retained marker for the void volume, was monitored at 205 nm.
Zonal elution experiments were conducted to initially evaluate the stability of the HDL
columns. The mobile phase was pH 7.4, 0.067 M potassium phosphate buffer that was
continuously applied to 1 cm × 2.1 mm i.d. columns containing the HDL silica or diol silica
control support. These experiments were conducted at 37 °C over the course of 300 h. A 20
μL sample of 1 μM R- or S-propranolol was injected onto the HDL column or control column
at 1.0 ml/min every 12 h to look for any changes in retention. The column void time was
measured by injecting 20 μL of 1 μM sodium nitrate. The retention time for each peak was
found by using its central moment, as determined by utilizing Peakfit 4.12 (Systat Software,
San Jose, CA, USA).
The frontal analysis studies were performed using the 5 cm × 2.1 mm i.d. HDL column and
control column. These studies were carried out at 4 °C, 27°C or 37°C and at 1.0 ml/min in the
presence of pH 7.4, 0.067 M potassium phosphate buffer. The use of slightly higher or lower
flow rates (0.4–1.2 ml/min) gave less than a 2% change in the measured binding capacities.
All of these studies were performed within the first 60 h of operation for each new HDL column;
this period was well within the usable time range for these columns, as determined in the zonal
elution studies (see Results and Discussion). A total of eleven mobile phase solutions
containing 0.1–25 μM R- or S-propranolol or six solutions containing 0.25–10 μM R/S-
verapamil were applied to the HDL column and control column. The retained analytes were
eluted by passing pH 7.4, 0.067 M potassium phosphate buffer through the column prior to the
next frontal analysis experiment. The amount of drug required to saturate the HDL column or
control column was determined by integration of the resulting breakthrough curve [3] using
Labview 5.1.
Interactions with system components other than HDL made up approximately 5–15% of the
total retention noted for R- and S-propranolol on an HDL column, and typically 15–22% of
the total retention for verapamil on an HDL column (note: such interactions are known to vary
from drug-to-drug on a given type of support and should always be evaluated on a case-by-
case basis) [3,31]. These interactions with the support did not create any difficulties in this
study because this binding was highly reproducible. In addition, an appropriate correction for
the void time and this non-specific binding was easily made by subtracting the breakthrough
time of the control column from that measured on the HDL column at each concentration of
an applied drug, as successfully used in past studies with the same drugs and other HPLC
supports or binding agents [5,6,26,32].
RESULTS AND DISCUSSION
General properties of HDL support
The composition of the HDL support was examined by using both a BCA protein assay and a
cholesterol assay. Based on the protein assay, the support was found to contain 68 (± 5) mg
HDL per gram silica. The cholesterol content of this same support was 3.4 (± 0.4) mg
cholesterol per gram silica. During long term storage in pH 7.4, 0.067 M potassium phosphate
buffer, the protein and cholesterol content of the HDL support were found to gradually decrease
by approximately the same relative amount. In the case of the protein content, there was a
decrease of 43 (± 4)% over three months, while the cholesterol content decreased by 56 (± 7)%
over the same period of time. However, the relative amount of cholesterol versus protein before
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and after storage was essentially the same, giving ratios that agreed within ±2 S.D. of their
respective values.
It is known that lipoproteins are macromolecular congregates that are held together by non-
covalent interactions. As such, these particles could potentially degrade or collapse when used
in flow-based system [7,8]. The consistency of the cholesterol-to-protein ratios measured
before and after three months of storage for the HDL silica suggests that the loss of either intact
or partial lipoprotein particles was responsible for the long term decrease in the support content
noted for this material, rather than the more selective loss of only apolipoproteins or cholesterol.
The fact that essentially half of the original HDL content still remained after three months of
storage in buffer was also encouraging in that it indicated the HDL support should be suitable
for use over shorter periods of time in a flow-based system employed in HPAC studies.
Column stability
The stability of the HDL support in a flow-based chromatographic system was next examined
by using zonal elution experiments in which periodic injections of R- or S-propranolol were
made onto this column under controlled temperature and flow rate conditions. Figure 3(a)
shows how the retention of R-propranolol changed on the HDL column when samples were
injected at 1 mL/min for over the course of 300 h at 37 °C. Similar results were obtained for
S-propranolol. Over the first four to five days of continuous use (i.e., 5.8–7.2 L of applied
buffer), the HDL column gave reproducible retention with retention times and retention factors
that varied by less than ± 5%. The amount of mobile phase applied during four to five days of
continuous operation corresponded to over 2 × 105 column volumes for a 1.0 cm × 2.1 mm i.d.
column. These data indicated that the HDL column was sufficiently stable for drug binding
studies under such conditions.
Following the first five days of use, a gradual loss of retention for R- and S-propranolol was
noted on the HDL column. After the equivalent of 12 days of continuous operation, the retention
factor for R-propranolol had fallen from its original value of 2.5–2.7 to just over 1.0, or a
decrease of roughly 9% per day after the first five days. Chiral separations for R- and S-
propranolol were not observed on the HDL column at any time during this study, in agreement
with previous results reported when using CE to examine the binding of R- and S-propranolol
to HDL [17].
Frontal analysis studies of propranolol binding to HDL
Figure 3(b) shows some typical frontal analysis curves that were obtained for R- or S-
propranolol on the HDL columns. These data were all collected within the period of time during
which the HDL columns were noted to be stable in the previous section (i.e., within the
equivalent of the first four to five days of continuous operation and over the course of
approximately 300 applications of sample). The mean position of each breakthrough curve
(mLapp) was determined and initially used along with the known concentration of applied drug
([A]) to generate double-reciprocal plots of 1/mLapp versus 1/[A], as shown in Figure 4. This
type of plot results in a linear relationship if a single type of binding is occurring; if more than
one type of interaction is present, the resulting plot will show negative deviations from a linear
response at high analyte concentrations [3]. The plots for R- and S-propranolol at all
temperatures examined in this study gave negative deviations from a linear response at large
analyte concentrations, or low values of 1/[A]. This behavior indicated that multiple types of
interactions were present during the binding of R- and S-propranolol with HDL.
Plots of mLapp versus [A] for R- and S-propranolol were also prepared using the frontal analysis
data. Examples of such graphs are given in Figure 5. The non-linear relationship noted in these
plots was fit to equations representing four distinct interaction models, as summarized in Table
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2. One type of interaction considered was site-specific binding by R- or S-propranolol, as might
occur to apolipoproteins on the surface of HDL [16–18]. A second type of interaction that was
investigated was non-saturable binding, as might be expected for interactions of R/S-
propranolol with the phospholipid layer or interior hydrophobic core of HDL [16–18].
Combinations of these interactions were also considered, such as the presence of two saturable
sites or the combination of one saturable site and a group of non-saturable interactions. Table
3 summarizes the best-fit binding parameters that were obtained for each of these models when
they were used to examine the frontal analysis data acquired for R- and S-propranolol on the
HDL columns.
It was already known from double reciprocal plots, such as those given in Figure 4, that multiple
interactions were present for R- and S-propranolol with the immobilized HDL. Thus, it was
not surprising that the non-reciprocal plots in Figure 5 gave a better fit with models that
involved more than one type of interaction. Although the single interaction models did give
good correlation coefficients for the plots in Figure 5 (r = 0.9993 to 0.9999), the residual plots
for these fits (see insets) represented a non-random distribution of data points about the best-
fit lines. In contrast to this, the multiple interaction models also gave large correlation
coefficients (i.e., 0.9998 to 0.9999 in all cases) as well as lower residuals and a more random
distribution of data about the best-fit lines than seen with the single interaction models.
The model giving the best overall fit to the data was one in which there was a high affinity
group of saturable sites and a lower affinity non-saturable interaction. It should be noted that
this multiple interaction model gave essentially the same correlation coefficient and residual
plot in Figure 5(c) as was obtained for the two-site saturable model in Figure 5(d) (e.g., values
for r greater than 0.9999). However, these two models did differ significantly in the precision
of their best-fit parameters, as shown in Table 3 by the standard deviations listed for Ka1,
mL1 and nKa in the saturable/non-saturable model versus those listed for Ka1, mL1, Ka2 and
mL1 in the two-site saturable model. This result can be explained by the fact that the equation
for the two-site saturable model approaches the equation for the combined saturable/non-
saturable interactions as Ka2 [D] becomes much smaller than one (see expressions in Table 2).
This situation was found to occur with the best-fit parameters determined for the two-site
saturable model in Table 3 and explains the large uncertainly in these particular parameters for
the propranol/HDL system. This observation also explains why the residual plots in Figures 5
(c) and Figure 5(d) were so similar because they were actually describing the same model in
which there was a high affinity saturable site and a set of lower affinity and essentially non-
saturable interactions.
Temperature studies and binding mechanism for propranolol with HDL
Table 4 summarizes the results that were obtained for R- and S-propranolol with HDL at several
temperatures when work was continued with a saturable/non-saturable multiple interaction
model. For R-propranolol, the saturable interaction had an association equilibrium constant
(Ka1) of 1.9 (± 0.8) × 105 at 37°C, which represents relatively high affinity and specific binding
for the interaction of a drug with a serum binding agent [2–6]. This binding is probably
occurring between R-propranolol and apolipoproteins on HDL, as supported by a comparison
of mL1 with the moles of apolipoproteins estimated to be present in the HDL column (see
following discussion). The second type of interactions had an overall affinity of 4.1 (± 0.3)
×104 M−1 at 37°C, which represents lower affinity and non-specific binding. This second
interaction is believed to occur between R-propranolol and phospholipids or the non-polar core
of HDL, as has been suggested in previous studies [16,17]. Similar values were found for S-
propranolol at 37°C.
The effect of temperature on the interactions between R- and S-propranolol and HDL was also
studied. The binding parameters determined for each enantiomer of propranolol with HDL are
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provided in Table 4. It was found that a change in temperature had no appreciable effect on
either the association equilibrium constants or binding capacities that were measured between
4°C and 37°C. The Ka1 values obtained for both R- and S-propranolol were consistently in the
range of 1.1 to 1.9×105 M−1 under these temperature conditions and the nKa2 values were all
in the range of 3.7 to 4.1×104 M−1. The correlation coefficients were greater than 0.9999 for
all frontal analysis plots that were analyzed according to a saturable/non-saturable model. The
Ka1 and n Ka2 values obtained for R- and S-propranolol were statistically identical at each
temperature (i.e., overlapping within a range of ± 1 S.D.). This result indicated that both types
of interactions in the saturable/non-saturable model were essentially non-stereoselective for
R/S-propranolol, as is also suggested by data given in Ref. [17]. In addition, the binding
parameters measured for the low affinity interactions gave good agreement with values
reported in the literature [16,17] when using a model based on a single type of non-saturable
interaction.
The nature of the high affinity binding sites was examined further by using comparing the
measured binding capacity of this site with the known composition of the HDL support. The
total moles of these high affinity sites was consistently in the range of 2.2 to 7.8 nmol for both
R- and S-propranolol between 4 and 37°C (average, 4.7 nmol and 5.4 nmol, respectively). It
was determined from the protein assay data that approximately 30 (± 2) nmol of immobilized
HDL was present in its column. The relatively strong binding of the high affinity sites and the
fact that their binding capacity was less than the total moles of HDL strongly suggests that
these particular interactions were due to apolipoproteins, for which only a few are present per
HDL particle (i.e., up to 5–6 maximum) [7]. The lower binding capacity for these high affinity
regions versus the moles of HDL may be due in part to immobilization effects, which can lead
to a 50% loss in activity for proteins in the coupling method that was employed in this report
[3]. However, it is also possible that only certain types of apolipoproteins may have been
involved in this high affinity interaction. The typical levels of apolipoproteins found in HDL
are ApoA1 (70%), ApoA2 (20%), and Apo E plus Apo C (10%) [7]. Further research is required
in the future to determine if there are indeed only particular apolipoproteins in this group that
bind to R/S-propranolol.
The relative importance of the saturable versus non-saturable interactions of R/S-propranolol
with HDL was estimated by considering the typical concentrations for each of these agents in
clinical samples. The reported therapeutic range for R/S-propranolol in serum is 0.19–0.39
μM [33], and a typical physiological concentration of HDL in serum is 13–14.6 μM [16,17].
Under these conditions, the high affinity and saturable interactions would be expected from
the data in Table 4 to account for 25–40% of the overall binding that occurs between R/S-
propranolol and HDL. In the experimental conditions that were employed for the CE studies
in Ref. [17], these high affinity sites would have been 85–97% saturated by R/S-propranolol
and would have accounted for only 1–10% of the overall measured binding, explaining why
these particular interactions were not directly observed in this previous study. A broader range
of R/S-propranolol concentrations were used in Ref. [16] in work with equilibrium dialysis,
but most of these concentrations were still sufficiently large to have made it difficult to detect
the high affinity interactions noted in this current study. In addition, it is important to remember
that even in this report a relatively good fit was seen for the data with a single site, non-saturable
model (see Figure 5). It was only through a close evaluation and comparison of this data with
several interaction models that it became clear that at least two types of interactions were
present between R/S-propranolol and HDL.
Frontal analysis studies of verapamil binding to HDL
Verapamil was a second drug used to evaluate binding by the HDL columns. In this case,
studies were conducted with racemic verapamil because HDL has been previously reported to
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have only non-stereoselective interactions with R- and S-verapamil [18]. As indicated earlier,
R- and S-propranolol were also found to have non-stereoselective binding to the HDL columns
used in this current study.
Figure 6 shows a non-reciprocal frontal analysis plot that was obtained for verapamil on an
HDL column. These results gave a curved response that deviated from the linear behavior
predicted for only non-saturable binding (see equation in Table 2). A correlation coefficient
of r = 0.9952 (n = 6) was obtained for the fit of a non-saturable model to these data; however,
this model also gave a non-random distribution of data about the best-fit line. A slightly higher
correlation coefficient (r = 0.9999) was obtained when using a model based on a single group
of saturable sites, but a non-random distribution of data about the best-fit line was also seen in
the corresponding residual plot (data not shown).
The model that gave the best-fit for the data in Figure 6 was again based on a group of saturable
sites and a set of non-saturable interactions (see summary in Table 4). The correlation
coefficient in this case was 0.9999 and only a random distribution of data about the best-fit
line was seen in the residual plot. In this fit, the sites responsible for saturable binding had an
association equilibrium constant for verapamil of 6.0 (± 2.1) × 104 at 37°C. The non-saturable
interaction of verapamil with HDL had an estimated overall affinity of 2.5 (± 1.5) 104 M−1.
These values gave good agreement with the overall affinities of 2.7–2.8 104 M−1 that have
been previously reported for the binding of R- and S-verapamil with soluble HDL [18].
A reasonable fit to the data in Figure 6 was also seen for a model in which there were two
groups of saturable sites with moderate or lower affinities for verapamil (r = 0.9999). In this
model, an association equilibrium constant of 6.3 (± 2.0) × 104 M−1 was obtained for the first
group of saturable sites for verapamil on HDL, giving a value similar to that generated by the
saturable/non-saturable model. The estimated association equilibrium constant for the second
group of saturable sites was 1.5×104 M−1, but this value had a large uncertainty of±2.4 × 106
M−1. This uncertainty plus the non-random distribution of data in the residual plot for the two
site saturable model indicated that the saturable/non-saturable model gave a better description
of the verapamil/HDL interaction. This conclusion was consistent with the results seen earlier
for R- and S-propranolol on the HDL columns.
It is interesting to note that the overall affinities were similar for the non-saturable interactions
of verapamil and propranolol with HDL. As discussed in the previous section, this binding is
probably the result of interactions between these drugs with phospholipids or the non-polar
core of HDL, as has been suggested for both propranolol and verapamil in work with soluble
HDL [16–18]. The affinity of verapamil at its saturable sites on HDL was roughly one third
the affinity measured for propranolol at its saturable regions, but these two drugs had a much
larger difference in the amount of these saturable sites. The amount of saturable sites for
verapamil was 54 (± 16) nmol in an HDL column, which was at least 10-times greater than the
average of 4.7–5.4 nmol that had been estimated for the saturable sites of R- or S-propranolol.
The binding capacity for verapamil at its saturable site was still comparable to the total moles
of immobilized HDL in the column (30 nmol) and the expected moles of apolipoproteins that
were present [7]. These results indicate that apoliproteins were probably responsible for the
saturable binding of verapamil with HDL, as was suggested earlier for propranolol. However,
the large difference in the binding capacities for verapamil and propranolol at their saturable
sites suggests that different subsets of apolipoproteins or different regions on these
apolipoproteins may be interacting with these two drugs.
The typical therapeutic concentration for R/S-verapamil in serum is 0.1–0.2 μM [32]. This
information was used along with the binding parameters in Table 4 and the known serum
concentration for HDL (13–14.6 μM) to examine the relative importance of saturable versus
Chen et al. Page 8
Anal Biochem. Author manuscript; available in PMC 2011 February 1.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
nonsaturable interactions in the binding of verapamil with HDL. Under normal therapeutic
conditions, the saturable interactions would account for about 70–80% of the overall binding
between R/S-verapamil and HDL. Under the experimental conditions used in Ref. [18], the
saturable sites would have accounted for roughly 40–60% of the overall measured binding.
However, the similarity in the affinities for the saturable and non-saturable sites of verapamil,
and the fact that only a non-saturable model was considered in Ref. [18], explains why these
saturable interactions were not noted in this previous solution-phase study.
CONCLUSIONS
HDL was immobilized in chromatographic columns and examined for use in drug binding
studies by HPAC. It was found that this type of column can be employed over four to five days
of consistent use without any significant loss of retention for R- and S-propranolol. Frontal
analysis experiments with these columns indicated that propranolol and verapamil had two
distinct interactions with HDL. One type of interaction had a moderately high affinity and
saturable binding and was believed to be due to apolipoproteins. The other interaction was non-
saturable and was believed to be due to the phospholipids or non-polar core of HDL. The high
affinity sites had association constants of 1.1–1.9 × 105 M−1for R/S-propranolol and 6.0 ×
104 M−1 for R/S-verapamil at 37°C. The overall affinity (nKa) for the weaker and non-saturable
interactions was 3.7–4.1 × 104 M−1 for R/S-propranolol and 2.5 × 104 M−1 for R/S-verapamil
at 37°C, in good agreement with previous solution-phase studies [16,17]. These interactions
appeared to be non-stereoselective, giving similar binding parameters for R- and S-propranolol
at temperatures ranging from 4 to 37°C.
These results demonstrate the feasibility of using HPAC to study the interactions of HDL with
drugs. Some advantages of this approach versus equilibrium dialysis (i.e., the method used in
Ref. [16] and a common reference method for drug binding studies) are the ability of HPAC
to obtain analysis times of only a few minutes per run and to reuse the same lipoprotein
preparation for many experiments. Although the use of CE in drug binding studies requires
less ligand for a single analysis, the ability to reuse the ligand in an HPAC column also results
in only a small amount of ligand being needed per sample. For instance, the CE studies in Ref.
[17] were conducted using approximately 1.5 pmol HDL per injection. In this current report a
single HDL column (containing 30 nmol HDL) was used for at least 300 experiments, or an
average of 10 pmol HDL per analysis. In addition, the use of the same HDL preparation for
multiple studies in HPAC makes it possible with this approach to reduce effects due to batch-
to-batch variations in the ligand. The advantage of utilizing HPLC detectors with such columns
also made it possible to examine a relatively wide range of drug concentrations. These last two
factors made it possible to identify moderately high affinity interactions between HDL and
propranolol or verapamil that had not previously been observed when using CE or equilibrium
dialysis [16–18]. All of these features indicate that HPAC columns containing immobilized
HDL can be useful and powerful tools in the study of drug-lipoprotein interactions.
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Figure 1.
(a) General structure of high density lipoprotein (HDL) and other lipoprotein particles, and the
structures of (b) propranolol and (c) verapamil, in which the asterisks indicate the locations of
the chiral centers in these drugs.
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Figure 2.
Immobilization of HDL onto silica by the Schiff base method.
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Figure 3.
(a) Change in the retention factor for R-propranolol as function of mobile phase volume for
pH 7.4, 0.067 M potassium phosphate buffer as it was passed through a 1 cm × 2.1 mm i.d.
HDL column at 1 ml/min and 37°C. (b) Typical frontal analysis results obtained for the
application of R-propranolol to a 5.0 cm × 2.1 mm i.d. HDL column at analyte concentrations
of 0.1, 0.2, 0.3, 0.4, 0.5, 1, 2, 5, 10 or 25 μM; these results were also obtained at 1.0 ml/min
and 37°C in the presence of pH 7.4, 0.067 M potassium phosphate buffer.
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Figure 4.
Double reciprocal plot of frontal analysis data obtained for the binding of R-propranolol to a
5.0 cm × 2.1 mm i.d. HDL column at 37°C in the presence of pH 7.4, 0.067 M potassium
phosphate buffer. The linear fit shown was obtained using data points in the upper region of
this plot, which are designated by the closed squares (■) and cover R-propranolol
concentrations that range from 0.1 μM to 2.5 μM. Data points in the lower region of this plot
(i.e., at higher concentrations of R-propranolol) and that showed negative deviations from the
linear fit to the upper data points are represented by open squares (□). An expansion of the
lower region of the graph is given in the inset. The equation for the best fit line to data
represented by the closed squares is y = 5.45 (± 0.07) × 102 x + 2.7 (± 0.6) × 108; the correlation
coefficient of this best fit line was 0.99985 (n = 12).
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Figure 5.
Examination of frontal analysis data for R-propranolol on an HDL column at 37°C according
to various binding models. These models were as follows: (a) one group of non-saturable
interactions, (b) one group of saturable sites, (c) two separate groups of saturable sites, and (d)
a group of non-saturable interactions plus a group of saturable sites. The insets show the
residual plots for the fit of each model to the experimental data. These results were obtained
in the presence of pH 7.4, 0.067 M potassium phosphate buffer. The correlation coefficients
were as follows: (a) 0.99937, n=12; (b) 0.99989, n = 12; (c) 0.99996, n = 12; and (d) 0.99996,
n = 12. The other best-fit parameters are summarized in Table 3.
Chen et al. Page 16
Anal Biochem. Author manuscript; available in PMC 2011 February 1.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
Figure 6.
Frontal analysis results for the binding of R/S-verapamil to an HDL column at 37°C. These
results were obtained in the presence of pH 7.4, 0.067 M potassium phosphate buffer. Other
conditions are given in the text. The best-fit line shown is for a model based on a group of non-
saturable interactions and a group of saturable sites, which gave a correlation coefficient of
0.99999 (n = 6). The other best-fit parameters are summarized in Table 4.
Chen et al. Page 17
Anal Biochem. Author manuscript; available in PMC 2011 February 1.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
Chen et al. Page 18
Table 1
Binding parameters previously reported for the interactions of propranolol and verapamil with HDL
Analyte
Overall
affinity,
n Ka
(M−1)a
Method [Ref.] Experimental Conditions
Racemic pH 7.4 Phosphate buffer(0.66 M)
Propranolol
1.60 ( ±
0.14) ×
104
Equilibrium dialysis [16] 13 μM HDL, 37°C 0.001–
1000μM Propranolol
R-Propranolol
2.38 ( ±
0.22) ×
104
High-performance Frontal analysis/capillary pH 7.4 Phosphate buffer (I =0.17) 14.6 μM HDL, 37°C
S-Propranolol
2.43 ( ±
0.15) ×
104
electrophoresis [17] 25–150 μM Propranolol
R-Verapamil
2.75 ( ±
0.61) ×
104
High-performance Frontal analysis/capillary pH 7.4 Phosphate buffer (I =0.17) 14.6 μM HDL, 37°C
S-Verapamil
2.81 ( ±
0.33) ×
104
electrophoresis [18] 25–100 μM Verapamil
I = ionic strength.
a
These results were obtained based on a single interaction model based on a group of non-saturable sites or a partition-like interaction [16–18]
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Table 2
Equations for various binding models that were used to fit frontal analysis data obtained for propranolol and
verapamil on HDL columns
Binding model Predicted response
Single non-saturable interaction mLapp = mL1Ka1[D]
Single group of saturable sites mLapp = (mL1Ka1[D])/(1 + Ka1[D])
Two interactions, saturable site + non-
saturable mLapp = (mL1Ka1[D])/(1 + Ka1[D]) + mL2Ka2[D]
Two groups of saturable sites mLapp = (mL1Ka1[D])/(1 + Ka1[D]) + (mL2Ka2[D])/(1 + Ka2[D])
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Table 4
Binding parameters determined for propranolol and verapamil on an HDL column using a two site, saturable/
one non-saturable binding modela
Temperature (°C) Ka1 (M−1) mL1 (mol) n Ka2 (M−l)b
R-Propranolol
4 1.4 (± 0.2) × 105 6.4 (± 0.8) × 10−9 3.7 (± 0.3) × 104
27 1.4 (± 0.2) × 105 5.4 (± 0.6) × 10−9 3.9 (± 0.3) × 104
37 1.9 (± 0.8) × 105 2.2 (± 0.7) × 10−9 4.1 (± 0.3) × 104
S-Propranolol
4 1.3 (± 0.5) × 105 7.8 (± 2.5) × 10−9 3.9 (± 0.3) × 104
27 1.6 (± 0.1) × 105 3.9 (± 0.2) × 10−9 4.0 (± 0.3) × 104
37 1.1 (± 0.1) × 105 4.5 (± 0.2) × 10−9 3.7 (± 0.2) × 104
R/S-Verapamil 37 6.0 (± 2.1) × 104 5.4 (± 16) × 10−8 2.5 (± 1.5) × 104
a
The numbers in parentheses represent a range of ± 1 S.D. All of these results were measured in the presence of pH 7.4, 0.067 M potassium phosphate
buffer.
b
The value for n Ka2 for the non-saturable interaction was calculated from the best-fit result for mL2 Ka2, as described in Table 3.
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